Adenosine A2A Receptor Antagonists for Parkinson’s Disease: Rationale, Therapeutic Potential and Clinical Experience

Author： Hauser Robert A.  

Publisher： Adis International

ISSN： 1170-229X

Source： Drugs & Aging, Vol.22, Iss.6, 2005-01, pp. : 471-482

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease

By Jenner Peter  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 729-738

Informa Healthcare

Access to resources Recommend Favorite

Adenosine A2A Receptor Antagonists and Parkinson's Disease: State of the Art and Future Directions

By  

Current Pharmaceutical Design, Vol. 14, Iss. 15, 2008-05 ,pp. : 1475-1489

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease

By Kaakkola S.  

Drugs, Vol. 59, Iss. 6, 2000-06 ,pp. : 1233-1250

Adis International

Access to resources Recommend Favorite

Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists

By Szabóó Nikoletta   Kincses Zsigmond Tamáás   Véécsei Láászlóó  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 4, 2011-04 ,pp. : 441-455

Informa Healthcare

Access to resources Recommend Favorite

Adenosine A 2A receptor antagonists as new agents for the treatment of Parkinson's disease

By Richardson P.J.   Kase H.   Jenner P.G.  

Trends in Pharmacological Sciences, Vol. 18, Iss. 9, 1997-10 ,pp. : 338-344

Elsevier

Access to resources Recommend Favorite